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EDITORIAL
Adjuvant chemotherapy of soft tissue sarcomaÐ current status
IAN JUDSON
Sarcoma Unit, Royal Marsden Hospital,London, UK
Itisacknowledgedthat,although improvementscan be
made in local control, e.g. by the use of adjuvant
radiotherapy,
1the major challenge in the management
of adult soft tissue sarcomas is the treatment of distant
metastatic disease.We lack very effective drugscapable
of providing long-term disease control once this event
has occurred. Palliation is possible with doxorubicin,
ifosfamide or combinations of these agents. However,
although more intensive treatment may increase the
response rate, long-term disease control is rare.
2
Randomised trials have failed to show a bene® t for
drug combinations over single-agent doxorubicin in
terms of progression-freeor overall survival.
3
Prevention of distant relapse would represent a
much better strategy if this were possible. Few
randomised trials have demonstrated a survival
advantage for adjuvant chemotherapy, although the
largest single study did show improved local control
in somesituations.
4A meta-analysis of publishedtrials
initially reported a survival advantage in favour of
chemotherapy;
5 however, a subsequent study of the
individual patient data, while demonstrating a 10%
improvement in relapse-free survival, failed to prove
a survival advantage.
6 There has been much debate
concerning these data; in particular, the fact that
many trials included patients with any grade of
tumour and also tumours at unfavourable sites, e.g.
uterus. There was a clear impression that patients
with extremity tumours were more likely to bene® t
from chemotherapy.
A small study has been conducted by the Italian
Sarcoma Group, in which only patients with high-
grade (grade III/IV), large (>5 cm) or recurrent,
extremity or limb girdle tumours were included.The
treatment comprised an aggressive combination of
high-dose ifosfamide and epirubicin, supported by
granulocyte-colonystimulating factor (G-CSF).This
study was closed in 1996 as a result of an interim
analysis that demonstrated a survival advantage. At
the time of the latest reported follow-up (1999), that
survival advantage was maintained.
7 This is a small
study in a selected group, with only 104 patients
randomised.However, the results are consistent with
the ® ndings of the meta-analysis.
The validity of the meta-analysis has also been
questioned for its inclusion of studies using single-
agentdoxorubicinand the generallylow-doseintensity
of the treatments used.Theadvocates of moreaggres-
sive treatment would cite the results of the Italian
trial as evidence for the value of intensi® cation. A
small feasibility study of intensive adjuvant
chemotherapy with ifosfamide,dacarbazine and doxo-
rubicin, together with hyperfractionated accelerated
radiotherapy, from the Austrian Sarcoma Study
Group is reported in this issue.
8This may represent
effective treatment, especially for those patients with
the highest risk of disease recurrence based on grade
and tumour size. However, the study was extremely
small and, as such, is of limited value. It is
acknowledged in the report that studies such as this
cannot be used as a guide to treatment.
A literature search for recent papers on adjuvant
chemotherapy in sarcoma revealed 247 reports on
adjuvant treatments but only four papers referred to
randomised trials, two of which related to the meta-
analysis and two were reviews.Verweij and Seynaeve
9
rightly emphasised the need to con® ne the use of
adjuvant chemotherapy to the investigational setting.
The European Organisation for Research and Treat-
mentof CancerSoftTissueand BoneSarcomaGroup
is currentlyconductinga prospective randomisedtrial
of adjuvant chemotherapy.The study designaddresses
someof the criticismsof previousstudies,by including
quality control of histopathological diagnosis and by
the early initiation of chemotherapy in those patients
randomised to treatment. This study uses a haemo-
poietic growth factor to allow an increase in the dose
of doxorubicin to 75 mg/m
2, but the dose of ifosfa-
mide, at 5 g/m
2, is modest. Perhaps, also increasing
the dose of ifosfamide is valuable in the adjuvant
setting, as reported by Frustaci et al.
7 and Brodowicz
et al.
8The challenge lies in being able to demonstrate
the true value of such aggressive approaches in
prospectiverandomisedtrials of sufficientsize to yield
meaningful results.
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